US FDA declines approval of Novartis' cholesterol-lowering drug
Updated : December 19, 2020 07:52:46 IST
US health regulator declined to approve inclisiran, the Swiss drugmaker’s potential treatment for elevated low-density cholesterol in adults
No onsite inspection was conducted by the FDA, the company said.
Published : December 19, 2020 07:52 PM IST